TDMS Study 96003-03 Pathology Tables
NTP Experiment-Test: 96003-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a) Report: PEIRPT02 Study Type: 39 WEEKS ALLYL BROMIDE Date: 03/30/01 Route: GAVAGE Time: 09:19:00 FINAL#1/MICE Facility: BIORELIANCE Chemical CAS #: 106-95-6 Lock Date: 10/18/00 Cage Range: All Reasons For Removal: All Removal Date Range: All Treatment Groups: Include 008 VEHICLE CONTROL Include 009 0.5 MG/KG Include 010 1 MG/KG Include 011 2 MG/KG Include 012 4 MG/KG Include 013 8 MG/KG Include 001 VEHICLE CONTROL Include 002 0.5 MG/KG Include 003 1 MG/KG Include 004 2 MG/KG Include 005 4 MG/KG Include 006 8 MG/KG a Number of animals examined microscopically at site and number of animals with lesion Page 1 NTP Experiment-Test: 96003-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a) Report: PEIRPT02 Study Type: 39 WEEKS ALLYL BROMIDE Date: 03/30/01 Route: GAVAGE Time: 09:19:00 ____________________________________________________________________________________________________________________________________ MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE VEHICLE 0.5 1 MG/KG 2 MG/KG 4 MG/KG 8 MG/KG CONTROL MG/KG ____________________________________________________________________________________________________________________________________ DISPOSITION SUMMARY Animals Initially in Study 15 15 15 15 15 15 Early Deaths Dosing Accident 2 Moribund Sacrifice 2 3 4 6 1 3 Natural Death 2 2 3 1 3 Survivors Terminal Sacrifice 9 10 8 8 11 12 Animals Examined Microscopically 15 15 15 15 15 15 ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM Liver (15) (15) (15) (15) (14) (15) Leukemia Erythrocytic 1 (7%) Lymphoma Malignant 2 (13%) 1 (7%) 1 (7%) Salivary Glands (3) Duct, Carcinoma 3 (100%) Stomach, Forestomach (14) (15) (12) (13) (14) (15) Squamous Cell Papilloma 5 (36%) 8 (53%) 4 (33%) 7 (54%) 5 (36%) 6 (40%) Squamous Cell Papilloma, Multiple 3 (21%) 2 (13%) 2 (17%) 2 (14%) 4 (27%) Tooth (2) (3) (6) (7) (3) (3) Odontogenic Tumor 2 (100%) 3 (100%) 6 (100%) 6 (86%) 2 (67%) 3 (100%) ____________________________________________________________________________________________________________________________________ CARDIOVASCULAR SYSTEM Heart (1) (1) Lymphoma Malignant 1 (100%) ____________________________________________________________________________________________________________________________________ ENDOCRINE SYSTEM Adrenal Cortex (13) (14) (12) (13) (12) (15) Lymphoma Malignant 1 (7%) Adrenal Medulla (13) (14) (12) (12) (12) (15) Lymphoma Malignant 1 (7%) Pituitary Gland (11) (14) (14) (13) (14) (14) Lymphoma Malignant 1 (8%) ____________________________________________________________________________________________________________________________________ Page 2 NTP Experiment-Test: 96003-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a) Report: PEIRPT02 Study Type: 39 WEEKS ALLYL BROMIDE Date: 03/30/01 Route: GAVAGE Time: 09:19:00 ____________________________________________________________________________________________________________________________________ MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE VEHICLE 0.5 1 MG/KG 2 MG/KG 4 MG/KG 8 MG/KG CONTROL MG/KG ____________________________________________________________________________________________________________________________________ GENERAL BODY SYSTEM None ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM Ovary (13) (15) (14) (14) (13) (15) Lymphoma Malignant 1 (8%) 1 (7%) Uterus (13) (15) (13) (14) (12) (15) Lymphoma Malignant 1 (7%) ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM Lymph Node, Mesenteric (13) (14) (12) (15) (12) (15) Lymphoma Malignant 1 (7%) Lymph Node, Mediastinal (14) (15) (14) (14) (12) (14) Lymphoma Malignant 1 (7%) Spleen (15) (14) (15) (15) (13) (15) Leukemia Erythrocytic 1 (7%) Lymphoma Malignant 2 (13%) 1 (7%) 1 (7%) ____________________________________________________________________________________________________________________________________ INTEGUMENTARY SYSTEM Skin (15) (15) (15) (15) (14) (15) Squamous Cell Papilloma 1 (7%) 1 (7%) 3 (20%) 3 (20%) 5 (36%) 1 (7%) Squamous Cell Papilloma, Multiple 1 (7%) Dermis, Fibrosarcoma 1 (7%) Lip, Squamous Cell Papilloma 1 (7%) 1 (7%) 1 (7%) 3 (20%) Vulva, Squamous Cell Papilloma 2 (13%) 4 (27%) 1 (7%) 5 (33%) 4 (29%) 6 (40%) Vulva, Squamous Cell Papilloma, Multiple 1 (7%) 1 (7%) 1 (7%) ____________________________________________________________________________________________________________________________________ MUSCULOSKELETAL SYSTEM None ____________________________________________________________________________________________________________________________________ Page 3 NTP Experiment-Test: 96003-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a) Report: PEIRPT02 Study Type: 39 WEEKS ALLYL BROMIDE Date: 03/30/01 Route: GAVAGE Time: 09:19:00 ____________________________________________________________________________________________________________________________________ MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE VEHICLE 0.5 1 MG/KG 2 MG/KG 4 MG/KG 8 MG/KG CONTROL MG/KG ____________________________________________________________________________________________________________________________________ NERVOUS SYSTEM None ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM Lung (14) (15) (15) (15) (14) (15) Alveolar/Bronchiolar Adenoma 2 (13%) Alveolar/Bronchiolar Carcinoma 1 (7%) Lymphoma Malignant 1 (7%) 1 (7%) ____________________________________________________________________________________________________________________________________ SPECIAL SENSES SYSTEM Harderian Gland (1) Adenoma 1 (100%) ____________________________________________________________________________________________________________________________________ URINARY SYSTEM Kidney (15) (14) (14) (15) (13) (15) Lymphoma Malignant 1 (7%) 1 (7%) 1 (7%) ____________________________________________________________________________________________________________________________________ SYSTEMIC LESIONS Multiple Organs *(15) *(15) *(15) *(15) *(15) *(15) Leukemia Erythrocytic 1 (7%) Lymphoma Malignant 2 (13%) 1 (7%) 1 (7%) ____________________________________________________________________________________________________________________________________ * Number of animals with any tissue examined microscopically Page 4 NTP Experiment-Test: 96003-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a) Report: PEIRPT02 Study Type: 39 WEEKS ALLYL BROMIDE Date: 03/30/01 Route: GAVAGE Time: 09:19:00 ____________________________________________________________________________________________________________________________________ MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE VEHICLE 0.5 1 MG/KG 2 MG/KG 4 MG/KG 8 MG/KG CONTROL MG/KG ____________________________________________________________________________________________________________________________________ TUMOR SUMMARY Total Animals with Primary Neoplasms (b) 10 13 10 14 11 14 Total Primary Neoplasms 16 21 19 25 21 27 Total Animals with Benign Neoplasms 9 10 8 9 11 14 Total Benign Neoplasms 12 16 10 18 19 22 Total Animals with Malignant Neoplasms 2 2 3 1 2 Total Malignant Neoplasms 2 2 3 1 2 Total Animals with Metastatic Neoplasms Total Metastatic Neoplasm Total Animals with Malignant Neoplasms Uncertain Primary Site Total Animals with Neoplasms Uncertain- Benign or Malignant 2 3 6 6 2 3 Total Uncertain Neoplasms 2 3 6 6 2 3 ____________________________________________________________________________________________________________________________________ a Number of animals examined microscopically at site and number of animals with lesion b Primary tumors: all tumors except metastatic tumors Page 5 NTP Experiment-Test: 96003-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a) Report: PEIRPT02 Study Type: 39 WEEKS ALLYL BROMIDE Date: 03/30/01 Route: GAVAGE Time: 09:19:00 ____________________________________________________________________________________________________________________________________ MICE:TGAC (FVB/N) HEMIZYGOUS MALE VEHICLE 0.5 1 MG/KG 2 MG/KG 4 MG/KG 8 MG/KG CONTROL MG/KG ____________________________________________________________________________________________________________________________________ DISPOSITION SUMMARY Animals Initially in Study 15 15 15 15 15 15 Early Deaths Moribund Sacrifice 2 2 3 2 4 1 Natural Death 1 3 3 4 2 Dosing Accident 1 1 1 1 Survivors Terminal Sacrifice 12 9 9 12 6 11 Animals Examined Microscopically 15 15 15 15 15 15 ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM Liver (14) (15) (14) (15) (14) (15) Leukemia Erythrocytic 1 (7%) 1 (7%) 1 (7%) Salivary Glands (1) (1) (1) Duct, Carcinoma 1 (100%) 1 (100%) 1 (100%) Stomach, Forestomach (15) (14) (14) (15) (13) (14) Squamous Cell Papilloma 5 (33%) 3 (21%) 5 (36%) 5 (33%) 5 (38%) 5 (36%) Squamous Cell Papilloma, Multiple 1 (7%) 2 (14%) 1 (7%) 1 (7%) Tooth (5) (5) (4) (3) (6) (4) Odontogenic Tumor 5 (100%) 5 (100%) 3 (75%) 3 (100%) 6 (100%) 3 (75%) ____________________________________________________________________________________________________________________________________ CARDIOVASCULAR SYSTEM None ____________________________________________________________________________________________________________________________________ ENDOCRINE SYSTEM None ____________________________________________________________________________________________________________________________________ GENERAL BODY SYSTEM None ____________________________________________________________________________________________________________________________________ Page 6 NTP Experiment-Test: 96003-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a) Report: PEIRPT02 Study Type: 39 WEEKS ALLYL BROMIDE Date: 03/30/01 Route: GAVAGE Time: 09:19:00 ____________________________________________________________________________________________________________________________________ MICE:TGAC (FVB/N) HEMIZYGOUS MALE VEHICLE 0.5 1 MG/KG 2 MG/KG 4 MG/KG 8 MG/KG CONTROL MG/KG ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM None ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM Spleen (15) (14) (14) (15) (14) (15) Leukemia Erythrocytic 1 (7%) 1 (7%) 1 (7%) ____________________________________________________________________________________________________________________________________ INTEGUMENTARY SYSTEM Skin (15) (15) (15) (15) (14) (15) Keratoacanthoma 3 (20%) Squamous Cell Papilloma 4 (27%) 1 (7%) 5 (33%) 2 (13%) 1 (7%) 1 (7%) Squamous Cell Papilloma, Multiple 1 (7%) 2 (13%) 1 (7%) 1 (7%) 3 (20%) Conjunctiva, Squamous Cell Carcinoma 1 (7%) Lip, Squamous Cell Papilloma 1 (7%) 1 (7%) 1 (7%) Lip, Squamous Cell Papilloma, Multiple 1 (7%) 1 (7%) ____________________________________________________________________________________________________________________________________ MUSCULOSKELETAL SYSTEM None ____________________________________________________________________________________________________________________________________ NERVOUS SYSTEM None ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM Lung (15) (15) (14) (15) (14) (15) Alveolar/Bronchiolar Adenoma 1 (7%) 1 (7%) 2 (14%) Alveolar/Bronchiolar Carcinoma 1 (7%) Carcinoma, Metastatic, Salivary Glands 1 (7%) Page 7 NTP Experiment-Test: 96003-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a) Report: PEIRPT02 Study Type: 39 WEEKS ALLYL BROMIDE Date: 03/30/01 Route: GAVAGE Time: 09:19:00 ____________________________________________________________________________________________________________________________________ MICE:TGAC (FVB/N) HEMIZYGOUS MALE VEHICLE 0.5 1 MG/KG 2 MG/KG 4 MG/KG 8 MG/KG CONTROL MG/KG ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM - cont Leukemia Erythrocytic 1 (7%) ____________________________________________________________________________________________________________________________________ SPECIAL SENSES SYSTEM None ____________________________________________________________________________________________________________________________________ URINARY SYSTEM None ____________________________________________________________________________________________________________________________________ SYSTEMIC LESIONS Multiple Organs *(15) *(15) *(15) *(15) *(15) *(15) Leukemia Erythrocytic 1 (7%) 1 (7%) 1 (7%) ____________________________________________________________________________________________________________________________________ * Number of animals with any tissue examined microscopically Page 8 NTP Experiment-Test: 96003-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a) Report: PEIRPT02 Study Type: 39 WEEKS ALLYL BROMIDE Date: 03/30/01 Route: GAVAGE Time: 09:19:00 ____________________________________________________________________________________________________________________________________ MICE:TGAC (FVB/N) HEMIZYGOUS MALE VEHICLE 0.5 1 MG/KG 2 MG/KG 4 MG/KG 8 MG/KG CONTROL MG/KG ____________________________________________________________________________________________________________________________________ TUMOR SUMMARY Total Animals with Primary Neoplasms (b) 11 10 11 11 12 10 Total Primary Neoplasms 18 14 22 15 17 14 Total Animals with Benign Neoplasms 9 5 9 9 8 7 Total Benign Neoplasms 13 7 17 11 9 10 Total Animals with Malignant Neoplasms 2 2 1 2 1 Total Malignant Neoplasms 2 2 1 2 1 Total Animals with Metastatic Neoplasms 1 Total Metastatic Neoplasm 1 Total Animals with Malignant Neoplasms Uncertain Primary Site Total Animals with Neoplasms Uncertain- Benign or Malignant 5 5 3 3 6 3 Total Uncertain Neoplasms 5 5 3 3 6 3 ____________________________________________________________________________________________________________________________________ a Number of animals examined microscopically at site and number of animals with lesion b Primary tumors: all tumors except metastatic tumors Page 9 ------------------------------------------------------------ ---------- END OF REPORT ---------- ------------------------------------------------------------